EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitSystematische Übersicht

A Systematic Review of Long-Term Safety Outcomes of Ketamine and Esketamine in Patients with Treatment-Resistant Depression

Tychique T Wasolua, Morgan S Hardy, Tanner J Bommersbach, Roger S McIntyre, Taeho Greg Rhee

Psychotherapy and Psychosomatics · 17.08.2026 · 1-1

DOI: 10.1159/pps/aemag005 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Psychotherapy and Psychosomatics, online erschienen am 17.08.2026. Verfasst von Tychique T Wasolua und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Public Health Sciences, University of Connecticut School of Medicine, Farmington, USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 63 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Approximately 30–40% of patients with major depressive disorder fail to respond to conventional antidepressants. Ketamine and esketamine are increasingly used in maintenance protocols extending months to years, yet synthesized data on cumulative safety remain limited. This systematic review evaluated long-term safety of both agents with follow-up ≥12 weeks.

Methods

MEDLINE, PsycINFO, Embase, and Cochrane Library were searched via OVID from inception through January 29, 2026. Eligible studies enrolled adults with depressive disorders receiving ketamine or esketamine with ≥12-week follow-up and extractable safety data. Risk of bias was assessed using RoB 2 (RCTs) and ROBINS-I v2 (nonrandomized studies). Safety outcomes were synthesized narratively across nine domains: neurocognitive, dissociative/psychotomimetic, sedation, cardiovascular, hepatic, urinary, misuse/dependence, suicidality, and serious adverse events (SAEs).

Results

Thirty-two studies (11 RCTs, 21 nonrandomized) met inclusion criteria, with follow-up ranging from 3 months to 9 years. Across cardiovascular, hepatic, and urinary domains, neither racemic ketamine nor intranasal esketamine demonstrated evidence of cumulative organ toxicity during maintenance treatment. Dissociative and sedative effects were common but consistently transient, resolving within 1–2 h of administration. No treatment-emergent neurocognitive dysfunction was identified; urologic complications were rare and resolved with treatment discontinuation. No cases of iatrogenic addiction, drug-seeking, or withdrawal were documented for either formulation. Suicidal ideation scores showed reductions from baseline, though suicide attempts and completions occurred during follow-up periods. SAEs attributable to treatment were rare. The comparative analyses suggested essentially equivalent long-term safety profiles between racemic ketamine and intranasal esketamine.

Conclusion

Over follow-up durations typically ranging from 3 to 12 months, current evidence supports the safety of ketamine and esketamine for TRD, with no cumulative organ toxicity or iatrogenic addiction during maintenance treatment. Acute effects remain transient and manageable. However, findings are limited by heterogeneity in safety monitoring across studies.

Schlagwörter

Stichwörter der Autor:innen

DepressionEsketamineKetamineSafety

Autor:innen und Institutionen

  • Department of Public Health Sciences, University of Connecticut School of Medicine, Farmington, USA.
  • Department of Psychiatry, Yale University School of Medicine, New Haven, USA.
  • Department of Psychiatry, University of Wisconsin School of Medicine and Public Health, Madison, USA.
  • Department of Psychiatry, University of Toronto, Toronto, Canada.
  • Department of Pharmacology and Toxicology, University of Toronto, Toronto, Canada.
  • Department of Public Health Sciences, University of Connecticut School of Medicine, Farmington, USA, tgrhee.research@gmail.com.

Zitieren

APA

Wasolua, T. T., Hardy, M. S., Bommersbach, T. J., McIntyre, R. S., & Rhee, T. G. (2026). A Systematic Review of Long-Term Safety Outcomes of Ketamine and Esketamine in Patients with Treatment-Resistant Depression. Psychotherapy and Psychosomatics, 1-1. https://doi.org/10.1159/pps/aemag005

Vancouver

Wasolua TT, Hardy MS, Bommersbach TJ, McIntyre RS, Rhee TG. A Systematic Review of Long-Term Safety Outcomes of Ketamine and Esketamine in Patients with Treatment-Resistant Depression. Psychotherapy and Psychosomatics. 2026:1-1. doi:10.1159/pps/aemag005

BibTeX
@article{Wasolua2026,
  author = {Wasolua, Tychique T and Hardy, Morgan S and Bommersbach, Tanner J and McIntyre, Roger S and Rhee, Taeho Greg},
  title = {A Systematic Review of Long-Term Safety Outcomes of Ketamine and Esketamine in Patients with Treatment-Resistant Depression},
  journal = {Psychotherapy and Psychosomatics},
  year = {2026},
  pages = {1--1},
  doi = {10.1159/pps/aemag005}
}
Kostenlos starten →